Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 206Prostatic Neoplasms 158Lung Neoplasms 93Stomach Neoplasms 69Neoplasms 69Head and Neck Neoplasms 60Squamous Cell Carcinoma of Head and Neck 56Neoplasm Metastasis 50Esophageal Neoplasms 49Ovarian Neoplasms 39Pancreatic Neoplasms 26Sarcoma 23Carcinoma, Ovarian Epithelial 20Urinary Bladder Neoplasms 19Unspecified Adult Solid Tumor, Protocol Specific 19Breast Neoplasms, Male 17Adenocarcinoma Of Esophagus 17Parkinson Disease 4, Autosomal Dominant Lewy Body 16Esophageal Squamous Cell Carcinoma 16Adenocarcinoma of Lung 16Fallopian Tube Neoplasms 14Carcinoma, Squamous Cell 14Adenocarcinoma 12Melanoma 11Inflammatory Breast Neoplasms 11Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Salivary Gland Neoplasms 8Endometrial Neoplasms 8

Interventions

Gemcitabine 6Pemetrexed 3Cisplatin 3Carboplatin 3atezolizumab 2Trastuzumab 2Sugammadex 2Paclitaxel 2Neostigmine 2vinflunine 1poly ICLC 1pembrolizumab 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1delta 24-sterol reductase 1daratumumab 1avelumab 1apatorsen 1abemaciclib 1Water 1Thalidomide 1Surveys and Questionnaires 1Saline Solution 1Rocuronium 1Nephroureterectomy 1Nephrectomy 1Neoadjuvant Therapy 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urologic Neoplasms × Docetaxel × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔